查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球周圍神經病變市場
市場調查報告書
商品編碼
1140709

2022-2029 年全球周圍神經病變市場

Global Peripheral Neuropathy Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

預計到 2021 年，周圍神經病變的市場規模將達到 15.39 億美元，在預測期間（2022-2029 年）以 4.2% 的複合年增長率增長。

外周神經病變是一種在大腦或脊髓與身體其他部位之間傳遞信息的神經受損或功能障礙的疾病。周圍神經構成了一個不可預知的系統，它將大腦和脊髓與肌肉、皮膚和內臟相連。周圍神經從脊髓發出。這些神經受損會干擾大腦與身體其他部位之間的交流，抑制肌肉發育並引起疼痛。

市場動態

周圍神經病變市場受到人口增長、糖尿病發病率上升、癌症治療化療藥物的增加以及對周圍神經病變的認識不斷提高的推動。

化療藥物的增長和慢性病患病率的上升預計將推動市場增長。

由於糖尿病的流行、用於癌症生長的化療藥物的興起以及對邊緣神經病變的態度不斷上升，周圍神經病變市場正在增長。例如，根據 2020 年國際糖尿病聯盟的數據，全球約有 4.93 億 20-79 歲的成年人患有糖尿病。預計到 2045 年，這一數字將增加並達到 7 億。糖尿病患者可能會因糖尿病而出現周圍神經病變。對一般人群的調查顯示，7% 到 18% 的成年人患有持續性神經病變，詳細頻率為每年 1000 人。在英國，26% 的糖尿病患者會出現邊緣性神經性疼痛。這些因素將在預測期內推動周圍神經病變市場的增長。

市場上知名企業擴大兼併、收購和合作，鼓勵組織通過創新進入新市場。例如，2019 年 2 月，梯瓦製藥工業有限公司推出仿製藥 Sabril 片劑進入美國市場。 Teva 擁有超過 550 種常規配方，擁有 FDA 批准的非獨家產品的最大放置位置，並在第一位置文件開口方面保持領先地位。這種藥片有嚴重的副作用，包括周圍神經病變。

周圍神經病變被認為是糖尿病患者進行非最差消融治療的最持久原因。收集的數據應在未來用於開發治療周圍神經病變的藥物和治療方法。

2019 年 12 月，InvaGen Pharmaceuticals, Inc. 將獲得美國食品藥品監督管理局 (US FDA) 對 25mg 至 300mg 普瑞巴林膠囊非正式新藥申請 (ANDA) 的最終批准。普瑞巴林膠囊適用於治療與糖尿病周圍神經病變相關的神經性疼痛。

預計與藥品相關的嚴格法規將阻礙市場增長。

由於周圍神經病變的複雜症狀，對治療劑的副作用和誤診的嚴格規定預計將阻礙預測期內的市場增長。

行業分析

全球外周神經病變市場根據包括波特五力、監管分析、供應鏈分析和定價分析在內的各種行業因素對市場進行了深入分析。

細分分析

在全球周圍神經病變市場中，糖尿病周圍神經病變部分預計將佔據最大的市場份額

按類型，周圍神經病變市場分為糖尿病周圍神經病變、化療引起的周圍神經病變、特發性周圍神經病變、HIV/AIDS 相關周圍神經病變等。由於糖尿病周圍神經病變在年輕糖尿病患者中的患病率不斷增加，糖尿病周圍神經病變部分佔據了最大的市場份額。糖尿病性神經病變是一種神經損傷，如果您患有糖尿病，可能會發生這種損傷。高血糖會損害全身的神經。糖尿病性神經病變經常損害腿部和足部的神經。據說大約 60% 到 70% 的糖尿病患者最終會發展為周圍神經病變，但並非所有人都患有疼痛。

化療引起的周圍神經病變領域預計將出現積極的市場增長，因為它通常用於接受化療的患者。雖然不同類別的化學治療師可以比較化療引起的周圍神經病變的臨床誘導，但每類藥物都被提出在不同的系統中引起神經病變，存在著令人生畏的對比。有人指出，神經病變的發生和發展背後有多種因素。大多數從臨床前研究中創建的藥理學操作員都忽略了減輕副作用。

隨著患者體驗的增加，HIV/AIDS 相關周圍神經病變的副作用通常包括消耗、僵硬、刺痛、震顫，以及腳趾和腳底傾斜死或缺失。手指、手和手腕的神經也會受到影響。一般來說，下肢疼痛可能表明神經病變越來越嚴重。根據 2021 年周圍神經病變基金會，估計約有 33% 的 HIV/AIDS 患者會出現某種形式的周圍神經病變。在 HIV/AIDS 患者中，周圍神經病變可由感染本身、用於治療 HIV/AIDS 的某些藥物、各種並發症或手部疾病引起。

此外，市場還根據藥物療法、非藥物療法、物理療法、手術等進行細分。由於一線治療在周圍神經病變治療中的大量使用，藥物治療部分佔據了最高的市場份額。例如，非甾體鎮靜劑 (NSAID)、抗抑鬱藥、鎮痛藥和抗癲癇藥被大量專業藥理學家單獨使用或混合使用以用於指定給藥。這些藥物提供適度的充分性、可能的症狀和依從性。

非藥物療法用於在不使用藥物的情況下減輕疼痛。這種治療應反映當時最成問題的行為症狀和患者的理解水平，並根據發育階段調整治療。

區域分析

北美在全球周圍神經病變市場中佔有最大份額

按地區劃分，北美主導著周圍神經病變市場。由於該地區糖尿病患病率的上升，預計在預測期內將以最高的複合年增長率增長。根據 2020 年皇家藥學會的數據，在加拿大，17.9% 的人口報告伴有神經性症狀的慢性疼痛，儘管加拿大最近的一項調查報告的比例較低。美國的一項研究發現，通過臨床檢查或自我報告確定的周圍神經病變的患□□病率分別為 9.8% 和 12.4%。該地區目睹了患有各種神經系統疾病的人的發病率上升，刺激了市場的增長。預計在預測期內，增加周圍神經病變治療的研發支出也將提振市場需求。

由於患有糖尿病和癌症等慢性病的老年人越來越多，預計亞太地區將佔據很大的市場份額。該地區的醫療保健部門正在發展，這正在推動市場發展。中國和印度等國家人口眾多，中產階級收入水平的提高為醫療保健支出創造了更多空間。這些因素在預測期內刺激了市場增長。

競爭格局

由於存在多個國際和國內市場，周圍神經病變市場是一個競爭激烈的市場。產品多樣化、收入安全和機會使市場更具競爭力。葛蘭素史克、雅培、Cipla 實驗室、諾華公司、默克公司、百時美施貴寶、Lady's Lab、輝瑞、禮來公司。禮來公司擁有重要的市場份額，已成為主要的市場參與者主要參與者正在利用產品開發、新產品發布、市場擴張和產品多元化戰略來維持其市場地位。

公司參與研究合作、合併、戰略合作夥伴關係、收購和新產品發布，以增加全球對周圍神經病變治療的需求。例如：

  • 2020 年 7 月，美國食品藥品監督管理局 (FDA) 批准了一種局部、非全身、非阿片類藥物疼痛治療，以貼片的形式提供，用於治療與足部周圍神經病變相關的神經性疼痛。已批准該藥物，昆坦薩。
  • 2020年7月，百時美施貴寶與藍鳥生物宣布聯合開發B細胞發育抗原（BCMA）協同致幻抗原受體（CAR）T細胞免疫療法，美國食品藥品監督管理局（FDA） ) for idecabtagene vicleucel. 宣布向 (FDA) 提交生物製品許可申請 (BLA)，用於治療患有背部和無法控制的大量骨髓瘤的成年患者。

值得關注的重點公司

Averitas 製藥

概述。它是 Grunenthal Group 的美國商業子公司，Grunenthal Group 是一家從事治療炎症、疼痛和痛風藥物研發的跨國製藥公司。其產品和服務部署在 30 多個國家。成立於2018年，總部位於德國。

按產品類型劃分的投資組合。

QUTENZA（辣椒素）：一種非全身性、非阿片類藥物，用於成人治療與帶狀皰疹後神經痛和糖尿病足部周圍神經病相關的神經性疼痛。

重大進展。 2021 年 3 月，Averitas Pharma 宣布進行一項 3 期研究，以觀察 QUTENZA 在術後神經性疼痛中的療效和安全性。

全球外周神經病變市場報告包括大約 45 多個市場數據表、40 多個數字和 180 頁。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 慢性病患病率上升
      • 增加化療藥物
    • 限制因素
      • 嚴格的規定
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 監管分析
  • 供應鏈分析
  • 定價分析

第 6 章按類型

  • 糖尿病周圍神經病變
  • 化療引起的周圍神經病變
  • 特發性周圍神經病
  • 其他

第 7 章治療

  • 藥物治療
    • 止痛藥
    • 抗驚厥藥
    • 抗抑鬱藥
  • 非藥物治療
    • 經皮神經電刺激療法
    • 血漿置換/靜脈注射免疫球蛋白治療
    • 其他

第 8 章最終用戶

  • 醫院
  • 診所
  • 門診
  • 其他

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 市場定位/市場份額分析
  • 併購分析

第 11 章公司簡介

  • Averitas Pharma
    • 公司簡介
    • 表格組合和說明
    • 主要亮點
    • 財務摘要
  • Cipla Laboratories
  • Merck and Co
  • Bristol Meyer Squibb
  • Reddy's Lab
  • Elli Lilly and Company
  • Teva Pharmaceutical Industries
  • GlaxoSmithKline
  • Novartis AG
  • Abbott Laboratories

第12章 全球周圍神經病變市場-DataM

簡介目錄
Product Code: DMPH2574

Market Overview

Peripheral Neuropathy Market size was valued US$ 1,539 million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 4.2% during the forecast period (2022-2029).

Peripheral neuropathy is a disorder when nerves that convey messages to and from the mind and spinal line from the remainder of the body are harmed or ailing. The peripheral nerves make up an unpredictable system that interfaces the brain and spinal string to the muscles, skin, and inside organs. Peripheral nerves come out of the spinal line. They are masterminded along lines in the body called dermatomes when damage to a nerve influence at least one dermatomes, which can be followed to specific regions of the body, harm to these nerves interferes with correspondence between the cerebrum and different pieces of the body and can disable muscle development and cause torment.

Market Dynamics

The peripheral neuropathy market is driven by the rising population, growing commonness of diabetes, increasing chemotherapy medicines for cancer growth, and rising mindfulness about fringe neuropathy.

Increasing chemotherapy medicines and rising prevalence of chronic diseases are expected to drive market growth.

The peripheral neuropathy market is expanding due to growing commonness of diabetes, increasing chemotherapy medicines for cancer growth, and rising mindfulness about fringe neuropathy. For instance, according to the International Diabetes Federation 2020, approximately 493 million adults of age-groups 20-79 have diabetes worldwide. This number is expected to increase and reach up to 700 million by 2045. Individuals with diabetes are probably going to experience the ill effects of diabetes-instigated fringe neuropathy. General population studies have revealed that 7% to 18% of adults now have incessant neuropathic torment, where the detailed frequency is 1000 individuals for every year. Alone, in the UK the 26% of people with diabetes experience fringe neuropathic torment. These factors will drive the growth of the peripheral neuropathy market in the forecast period.

Expanding mergers, acquisitions, and coordinated efforts by conspicuous players in the market encourage organizations to enter the new market with inventive innovations. For instance, in February 2019, Teva Pharmaceutical Industries Ltd launched a generic version of Sabril tablets to enter the US market. With more than 550 conventional prescriptions accessible, Teva has the biggest arrangement of FDA-endorsed nonexclusive items and holds the main situation in first-to-document openings. The tablets have serious side effects include peripheral neuropathy.

Peripheral neuropathy is perceived as the most continuous reason for non-awful removal in diabetic patients. The Neuropathy Association makes attention to peripheral neuropathy by furnishing patients with the essential assets, data, and apparatuses to manage to discover medicines. The collected data should be used to develop pharmaceuticals and the treatment of peripheral neuropathy in the future.

In December 2019, InvaGen Pharmaceuticals, Inc., get final approval for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules of 25mg to 300mg from the United States Food and Drug Administration (US FDA). Pregabalin capsules are indicated for the cure of neuropathic pain associated with diabetic peripheral neuropathy.

Stringent regulations associated with the medications are expected to hamper the market growth.

The stringent regulations regarding the side effects of the medicines use in the treatment, and the misdiagnosis of peripheral neuropathy due to its complex array of symptoms will hinder the market growth in the forecast period.

Industry Analysis

The global peripheral neuropathy market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis and pricing analysis.

Segment Analysis

Diabetic peripheral neuropathy segment is expected to hold the largest market share in global peripheral neuropathy market

The peripheral neuropathy market is segmented by type into diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, idiopathic peripheral neuropathy, HIV/AIDS associated peripheral neuropathy and others. The diabetic peripheral neuropathy segment held the largest market share due to the increasing prevalence of diabetic peripheral neuropathy in youth suffering from diabetes. Diabetic neuropathy is a kind of nerve harm that can happen if you have diabetes. High blood sugar will harm nerves all through the body. Diabetic neuropathy regularly harms nerves in the legs and feet. About 60% to 70% of all people with diabetes will eventually develop peripheral neuropathy, although not all suffer pain.

The Chemotherapy-induced peripheral neuropathy segment is expected to have positive market growth due to its use common in patients receiving anticancer treatment. Although chemotherapy-induced peripheral neuropathy's clinical introduction can be comparable with the different classes of chemotherapeutic specialists, there are unpretentious contrasts, proposing that each class of medications may incite neuropathy using various systems. Different components have been proposed to underlie the turn of events and support of neuropathy. Most pharmacological operators created from preclinical trials have neglected to reduce the side effects.

HIV/AIDS associated peripheral neuropathy side effects on patients as a rule experience incorporate consuming, firmness, prickling, shivering, and deadness or lost inclination in the toes and bottoms of the feet. The nerves in the fingers, hands, and wrists are additionally influenced. Generally extraordinary, torment over the lower legs could show increasingly serious nerve harm. According to the Foundation for Peripheral Neuropathy 2021, it is estimated that about 33% of individuals with HIV/AIDS experience some fringe nerve harm. For patients with HIV/AIDS, peripheral neuropathy can be brought about by the infection itself, by specific medications utilized in the treatment of HIV/AIDS or different intricacies, or because of deft diseases.

Further, the market is also classified based on pharmacological therapies, non-pharmacological therapies, physical therapies, surgery, and others. The pharmacological therapies segment accounts for the highest market share due to the high usage of primary in peripheral neuropathy treatment. A huge array of pharmacologic specialists, for example, nonsteroidal calming drugs (NSAIDs), antidepressants, analgesics, and antiepileptic drugs, are utilized alone or in the blend for indicative administration. These medications bring about moderate adequacy, possible symptoms, and medication cooperation.

Non-Pharmacological therapies are used to decrease pain without the use of medicine. In this therapy, the treatments should be modified for the developmental stages, reflecting both the most problematic behavioral symptoms at that stage in time and the patient's level of understanding.

Geographical Analysis

North America region holds the largest market share in the global peripheral neuropathy market

By region, North America is dominating the peripheral neuropathy market. It is expected to grow at the highest CAGR over the forecast period due to the increasing prevalence of diabetes in the region. According to the Royal Pharmaceutical Society 2020, in Canada, 17.9% of the population reported chronic pain with neuropathic symptoms; however, a recent Canadian study has reported lower percentages. A study in the United States revealed that the prevalence rates for peripheral neuropathy determined by either clinical examination or self-reporting were 9.8% and 12.4%, respectively. The rising incidences of people suffering from various neuropathy problems in the region have fueled the market's growth. The higher spending on the research and development activities for treating peripheral neuropathy shall boost the market demand over the forecast period.

The Asia-Pacific region is expected to have a large market share due to the increasing number of geriatric populations afflicted with chronic diseases like diabetes and cancer. The developing healthcare sector in the region has boosted the market. Countries like China and India have a huge population; also, the rise in the middle class's income level has given them the capacity to spend on health care. These factors stimulate market growth over the forecasted period.

Competitive Landscape

The peripheral neuropathy market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. GlaxoSmithKline, Abbott Laboratories, Cipla Laboratories, Novartis AG, Merck and Co., Bristol Meyer Squibb, Reddy's Lab, Pfizer and Elli Lilly and Company, Eli Lilly are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.

The companies enter into collaborations, mergers, strategic partnerships, acquisitions and novel product launches to increase the demand for peripheral neuropathy treatment across the globe. For instance,

  • In July 2020, The Food and Drug Administration (FDA) had approved Qutenza, a topical, non-systemic, non-opioid pain treatment delivered in the form of a patch for neuropathic treatment pain with peripheral neuropathy of the feet.
  • In July 2020, Bristol Myers Squibb and bluebird bio reported the accommodation of their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for idecabtagene vicleucel, the organizations' investigational B-cell development antigen (BCMA)- coordinated illusory antigen receptor (CAR) T cell immunotherapy, for the treatment of grown-up patients with backslid and unmanageable numerous myeloma.

Key Companies to Watch

Averitas Pharma:

Overview: It is an US commercial subsidiary of Grunenthal group, a multinational pharma company that works in research and development of therapeutics for inflammation, pain and gout. Its products and services are present in over 30 countries. It was founded in 2018 and is headquartered in Germany.

Product Type Portfolio:

QUTENZA (Capsaicin): It is a non-systemic and non-opioid that is used in adults for neuropathic pain treatment that is linked with postherpetic neuralgia and diabetic peripheral neuropathy of feet.

Key Developments: In Mar 2021, Averitas pharma announced about conducting phase III trial of QUTENZA to observe its efficacy and safety in post-surgical neuropathic pain.

The global peripheral neuropathy market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. Rising Incidence of Chronic Diseases
      • 4.1.1.2. Increasing chemotherapy medicines
    • 4.1.2. Restraints:
      • 4.1.2.1. Stringent regulations
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Regulatory Analysis
  • 5.3 Supply Chain Analysis
  • 5.4 Pricing Analysis

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Diabetic Peripheral Neuropathy
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 6.3. Chemotherapy-induced Peripheral Neuropathy
  • 6.4. Idiopathic Peripheral Neuropathy
  • 6.5. Others

7. By Treatment

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 7.1.2. Market Attractiveness Index, By Treatment
  • 7.2. Pharmacological Therapies
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Pain Relievers
    • 7.2.4. Anti-seizure Medications
    • 7.2.5. Antidepressants
  • 7.3. Non-pharmacological Therapies
    • 7.3.1. Transcutaneous Electrical Nerve Stimulation
    • 7.3.2. Plasma Exchange and Intravenous Immune Globulin
    • 7.3.3. Others

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, USD Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Clinics
  • 8.4. Ambulatory Centers
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. The U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. The Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Averitas Pharma
    • 11.1.1. Company Overview
    • 11.1.2. Form Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Cipla Laboratories
  • 11.3. Merck and Co
  • 11.4. Bristol Meyer Squibb
  • 11.5. Reddy's Lab
  • 11.6. Elli Lilly and Company
  • 11.7. Teva Pharmaceutical Industries
  • 11.8. GlaxoSmithKline
  • 11.9. Novartis AG
  • 11.10. Abbott Laboratories

LIST NOT EXHAUSTIVE

12. Global Peripheral Neuropathy Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Method of Fixation
  • 12.3. Contact Us